| Bioactivity | JAK3/BTK-IN-4 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-4 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147953A1, compound 003)[1] |
| Name | JAK3/BTK-IN-4 |
| CAS | 2673196-38-6 |
| Formula | C21H25ClN8O |
| Molar Mass | 440.93 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Baoguo Zhang, et al. Pyrimidinopyrimidine and pentacyclic derivatives and their applications. Patent WO2021147953A1. |
JAK3/BTK-IN-4
CAS: 2673196-38-6 F: C21H25ClN8O W: 440.93
JAK3/BTK-IN-4 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simulta
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.